Dialysis prescription: A modifiable risk factor for chronic kidney disease patients

Blood Purification

Volumn 29, Issue 4, 2010, Pages 366-374

  Canaud, Bernard ^a   Wabel, Peter ^b   Tetta, Ciro ^b  

^a LAPEYRONIE HOSPITAL   (France)

^b FRESENIUS MEDICAL CARE   (Germany)

Author keywords

Dialysis adequacy; Dialysis prescription; Mortality

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; BETA 2 MICROGLOBULIN; CALCIUM; PHOSPHATE; PHOSPHORUS; UREMIC TOXIN;

ANEMIA; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CATHETER; CHRONIC KIDNEY DISEASE; DIALYSIS; FLUID BALANCE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INFLAMMATION; MEDICAL PRACTICE; MORBIDITY; MORTALITY; PATIENT CARE; PHOSPHATE BLOOD LEVEL; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK FACTOR; SUPPLEMENTATION; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UREMIA; VASCULAR ACCESS; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

HUMANS; PRESCRIPTIONS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 77950619990     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000309422     Document Type: Review

References (80)

1. Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, Piera L, Bragg-Gresham JL, Feldman HI, Goodkin DA, Gillespie B, Wolfe RA, Held PJ, Port FK: Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 108-120. (Pubitemid 38072622)
2. Goodkin DA, Young EW, Kurokawa K, Prütz KG, Levin NW: Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis 2004; 44(suppl 2):16-21. (Pubitemid 39369936)
3. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270-3277. (Pubitemid 37509303)
4. Bradbury BD, Fissell RB, Albert JM, Anthony MS, Critchlow CW, Pisoni RL, Port FK, Gillespie BW: Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2007; 2: 89-99.
5. Portolés J, López-Gómez JM, Gruss E, Aljama P; MAR Study Group: Course of vascular access and relationship with treatment of anemia. Clin J Am Soc Nephrol 2007; 2: 1163-1169.
6. Thomson PC, Stirling CM, Geddes CC, Morris ST, Mactier RA: Vascular access in haemodialysis patients: a modifiable risk factor for bacteraemia and death. QJM 2007; 100: 415-422.
7. Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, Kooman J, Martin-Malo A, Pedrini L, Pizzarelli F, Tattersall J, Vennegoor M, Wanner C, ter Wee P, Vanholder R: EBPG on vascular access. Nephrol Dial Transplant 2007; 22(Suppl 2):ii88-ii117.
8. Sands JJ: Increasing AV fistulae and decreasing dialysis catheters: two aspects of improving patient outcomes. Blood Purif 2007; 25: 99-102.
9. Gonsalves CF, Eschelman DJ, Sullivan KL, DuBois N, Bonn J: Incidence of central vein stenosis and occlusion following upper extremity PICC and port placement. Cardiovasc Intervent Radiol 2003; 26: 123-127. (Pubitemid 36919551)
10. Allon M, Lockhart ME, Lilly RZ, Gallichio MH, Young CJ, Barker J, Deierhoi MH, Robbin ML: Effect of preoperative sonographic mapping on vascular access outcomes in hemodialysis patients. Kidney Int 2001; 60: 2013-2020. (Pubitemid 33000008)
11. Konner K, Hulbert-Shearon TE, Roys EC, Port FK: Tailoring the initial vascular access for dialysis patients. Kidney Int 2002; 62: 329-338. (Pubitemid 34754079)
12. Rayner HC, Besarab A, Brown WW, Disney A, Saito A, Pisoni RL: Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. Am J Kidney Dis 2004; 44(suppl 2):22-26. (Pubitemid 39369937)
13. Lemaire X, Morena M, Leray-Moragués H, Henriet-Viprey D, Chenine L, Defez-Fougeron C, Canaud B: Analysis of risk factors for catheter-related bacteremia in 2000 permanent dual catheters for hemodialysis. Blood Purif 2009; 28: 21-28.
14. Meeus G, Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y: A prospective, randomized, double-blind crossover study on the use of 5% citrate lock versus 10% citrate lock in permanent hemodialysis catheters. Blood Purif 2005; 23: 101-105. (Pubitemid 40470290)
15. Kritchevsky SB, Braun BI, Kusek L, Wong ES, Solomon SL, Parry MF, Richards CL, Simmons B; Evaluation of Processes and Indicators in Infection Control (EPIC) Study Group: The impact of hospital practice on central venous catheter associated bloodstream infection rates at the patient and unit level: a multicenter study. Am J Med Qual 2008; 23: 24-38.
16. Jaffer Y, Selby NM, Taal MW, Fluck RJ, Mc-Intyre CW: A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheter-related infection. Am J Kidney Dis 2008; 51: 233-241.
17. Canaud B, Leray-Moragues H, Garrigues V, Mion C: Permanent twin catheter: a vascular access option of choice for haemodialysis in elderly patients. Nephrol Dial Transplant 1998; 13(suppl 7):82-88. (Pubitemid 28534781)
18. Gotch FA: Evolution of the single-pool urea kinetic model. Semin Dial 2001; 14: 252-256.
19. Gotch F: The basic, quantifiable parameter of dialysis prescription is Kt/V urea; treatment time is determined by the ultrafiltration requirement; all three parameters are of equal importance. Blood Purif 2007; 25: 18-26. (Pubitemid 46005746)
20. Locatelli F, Buoncristiani U, Canaud B, Köhler H, Petitclerc T, Zucchelli P: Haemodialysis with on-line monitoring equipment: tools or toys ? Nephrol Dial Transplant 2005; 20: 22-33. (Pubitemid 40207604)
21. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019. (Pubitemid 35461657)
22. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G: Serumβ -2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006; 17: 546-555.
23. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R; Membrane Permeability Outcome (MPO) Study Group: Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20: 645-654.
24. Spalding EM, Chamney PW, Farrington K: Phosphate kinetics during hemodialysis: evidence for biphasic regulation. Kidney Int 2002; 61: 655-667. (Pubitemid 34102609)
25. Ward RA, Greene T, Hartmann B, Samtleben W: Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int 2006; 69: 1431-1437.
26. Ozkahya M, Ok E, Toz H, Asci G, Duman S, Basci A, Kose T, Dorhout Mees EJ: Longterm survival rates in haemodialysis patients treated with strict volume control. Nephrol Dial Transplant 2006; 21: 3506-3513. (Pubitemid 44817101)
27. Weinreich T, De los Ríos T, Gauly A, Passlick-Deetjen J: Effects of an increase in time vs. frequency on cardiovascular parameters in chronic hemodialysis patients. Clin Nephrol 2006; 66: 433-439. (Pubitemid 44896152)
28. Ng TG, Johnson DW, Hawley CM: Is it time to revisit residual renal function in haemodialysis? Nephrology 2007; 12: 209-217.
29. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR, Tonelli M, Donnelly S, Friedrich MG, Kumar A, Mahallati H, Hemmelgarn BR, Manns BJ: Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007; 298: 1291-1299. (Pubitemid 47443343)
30. Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C, Bommer J, Akiba T, Mapes DL, Young EW, Port FK: Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006; 69: 1222-1228.
31. Marshall MR, Byrne BG, Kerr PG, McDonald SP: Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int 2006; 69: 1229-1236.
32. Yashiro M, Kamata T, Segawa H, Murakami T, Kadoya Y, Muso E: How does higher ultrafiltration within the conventional clinical range impact the volume status of hemodialysis patients? Blood Purif 2009; 27: 253-260.
33. Rocco MV, Yan G, Heyka RJ, Benz R, Cheung AK; Hemo Study Group: Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Am J Nephrol 2001; 21: 280-288. (Pubitemid 32757311)
34. Wabel P, Moissl U, Chamney P, Jirka T, Machek P, Ponce P, Taborsky P, Tetta C, Velasco N, Vlasak J, Zaluska W, Wizemann V: Towards improved cardiovascular management: the necessity of combining blood pressure and fluid overload. Nephrol Dial Transplant 2008; 23: 2965-2971.
35. Katz AM: Heart Failure; in Fozzard HA, et al (eds): The Heart and Cardiovascular System, ed 2. New York, Raven Press, 1992, pp 333-353.
36. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predilaysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347-354. (Pubitemid 26075843)
37. Mark PB, Johnston N, Groenning BA, Foster JE, Blyth KG, Martin TN, Steedman T, Dargie HJ, Jardine AG: Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006; 10: 1839-1845. (Pubitemid 43739213)
38. Chan CT, Floras JS, Miller JA, Richardson RMA, Pierratos A: Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002; 61: 2235-2239. (Pubitemid 34539341)
39. Hegstrom RM, Murray JS, Pendras J, Burnell JM, Scribner BH: Hemodialysis in the treatment of chronic uremia. Trans Am Soc Artif Intern Organs 1961; 7: 136-149.
40. Ozkahya M, Ok E, Toz H, Asci G, Duman S, Basci A, Kose T, Dorhout Mees EJ: Longterm survival rates in haemodialysis patients treated with strict volume control. Nephrol Dial Transplant 2006; 21: 3506-3543. (Pubitemid 44817101)
41. Ifudu O: The concept of dry weight in maintenance hemodialysis: flaws in clinical application. Int J Artif Organs 1996: 19: 384-386.
42. Leypoldt JK, Cheung AK, Delmez JA, Gassman JJ, Levin NW, Lewis JA, Lewis JL, Rocco MV: Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int 2002; 61: 266-275. (Pubitemid 34075154)
43. Kooman JP, van der Sande FM, Leunissen KM: Role of sodium and volume in the pathogenesis of hypertension in dialysis patients: reflections on pathophysiological mechanisms. Blood Purif 2004; 22: 55-59.
44. Lins LE, Hedenborg G, Jacobson SH, Samuelson K, Tedner B, Zetterholm UB, Ljungqvist O: Blood pressure reduction during hemodialysis correlates to intradialytic changes in plasma volume. Clin Nephrol 1992: 37: 308-313.
45. Lucas MF, Quereda C, Teruel JL, Orte L, Marcen R, Ortuno J: Effect of hypertension before beginning dialysis on survival of hemodialysis patients. Am J Kidney Dis 2003; 41: 814-821. (Pubitemid 36396749)
46. Sherman RA, Daniel A, Cody RP: The effect of interdialytic weight gain on predialysis blood pressure. Artif Organs 1993: 17: 770-774. (Pubitemid 23288687)
47. Ventura JE, Sposito M: Volume sensitivity of blood pressure in end-stage renal disease. Nephrol Dial Transplant 1997; 12: 485-491. (Pubitemid 27105623)
48. Dorhout Mees EJ: Cardiovascular Aspects of Dialysis Treatment; The Importance of Volume Control, ed 1. Dordrecht, Kluwer Academic Publishers, 2000.
49. Port F: End-stage renal disease: magnitude of the problem, prognosis of future trends and possible solutions. Kidney Int 1995; 50:S3-S6.
50. Charra B: Fluid balance, dry weight, and blood pressure in dialysis. Hemodialysis Int 2007; 11: 21-31. (Pubitemid 46128675)
51. Katzarski KS, Charra B, Laurent G, Lopot F, Divino-Filho JC, Bergstrom J: Multifrequency bioimpedance in assessment of dry weight in haemodialysis. Nephrol Dial Transplant 1996; 11(suppl 2):20-23. (Pubitemid 26182538)
52. Lopot F, Nejedly B, Novotna H, Mackova M, Sulkova S: Age-related extracellular to total body water volume ratio (Ecv/TBW) -can it be used for dry weight determination in dialysis patients? Application of multifrequency bioimpedance measurement. Int J Artif Organs 2002; 25; 8: 762-769.
53. Wizemann V, Schilling M: Dilemma of assessing volume state -the use and limitations of a clinical score. Nephrol Dial Transplant 1995; 10: 2114-2117.
54. Chamney PW, Kraemer M, Rode C, Kleinekofort W, Wizemann V: A new technique for establishing dry weight in hemodialysis patients via whole body bioimpedance. Kidney Int 2002; 61: 2250-2258. (Pubitemid 34539343)
55. Chamney PW, Wabel P, Moissl UM, Muller MJ, Bosy-Westphal A, Korth O, Fuller NJ: A whole-body model to distinguish excess fluid from the hydration of major body tissues. Am J Clin Nutr 2007; 85: 1:80-89. (Pubitemid 46067619)
56. Kraemer M, Rode C, Wizemann V: Detection limit of methods to assess fluid status changes in dialysis patients. Kidney Int 2006; 69: 1609-1620.
57. Wabel P, Chamney P, Moissl U, Jirka T: Importance of whole-body bioimpedance spectroscopy for the management of fluid balance. Blood Purif 2009; 1: 75-80.
58. Wizemann V, Wabel P, Chamney P, Zaluska W, Moissl U, Rode C, Malecka-Masalska T, Marcelli D: The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 5:1574-1579.
59. Machek P, Jirka T, Chamney P, Moissl U, Wabel P: Guided optimisation of fluid status in haemodialysis patients. Nephrol Dial Transplant 2010;25:538-544.
60. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W; European Uremic Toxin Work Group (EUTox): Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943. (Pubitemid 36513344)
61. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J; European Uremic Toxin Work Group: A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008; 19: 863-870.
62. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187. (Pubitemid 41623345)
63. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G: Serumβ -2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006; 17: 546-555.
64. Cheung AK, Greene T, Leypoldt JK, Yan G, Allon M, Delmez J, Levey AS, Levin NW, Rocco MV, Schulman G, Eknoyan G; HEMO Study Group: Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 69-77.
65. Canaud B, Morena M, Cristol JP, Krieter D: β2-Microglobulin, a uremic toxin with a double meaning. Kidney Int 2006; 69: 1297-1299.
66. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y: Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087. (Pubitemid 43372184)
67. Chauveau P, Nguyen H, Combe C, Chêne G, Azar R, Cano N, Canaud B, Fouque D, Laville M, Leverve X, Roth H, Aparicio M; French Study Group for Nutrition in Dialysis: Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis 2005; 45: 565-571.
68. Krane V, Krieter DH, Olschewski M, März W, Mann JF, Ritz E, Wanner C: Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis 2007; 49: 267-275. (Pubitemid 46178399)
69. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G: Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003; 14: 3251-3263. (Pubitemid 37509301)
70. Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T, Klassen P, Port FK: Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 69: 2087-2093. (Pubitemid 43924275)
71. Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, Barsotti G, Rindi P, Donati G, Antonelli A, Panicucci E, Tripepi G, Tetta C, Palla R; RISCAVID Study Group: Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies -results from the RISCAVID study. Nephrol Dial Transplant 2008; 23: 2337-2343. (Pubitemid 351957592)
72. Canaud B, Morena M, Leray-Moragues H, Chalabi L, Cristol JP: Overview of clinical studies in hemodiafiltration: what do we need now? Hemodial Int 2006; 10(suppl 1): S5-S12. (Pubitemid 43263301)
73. Vanholder R, Eloot S, Van Biesen W: Do we need new indicators of dialysis adequacy based on middle-molecule removal? Nat Clin Pract Nephrol 2008; 4: 174-175. (Pubitemid 351451295)
74. Ward RA: Ultrapure dialysate: a desirable and achievable goal for routine hemodialysis. Semin Dial 2000; 13: 378-380.
75. Penne EL, Visser L, van den Dorpel MA, van der Weerd NC, Mazairac AH, van Jaarsveld BC, Koopman MG, Vos P, Feith GW, Kremer Hovinga TK, van Hamersvelt HW, Wauters IM, Bots ML, Nubé MJ, Ter Wee PM, Blankestijn PJ, Grooteman MP: Microbiological quality and quality control of purified water and ultrapure dialysis fluids for online hemodiafiltration in routine clinical practice. Kidney Int 2009; 76: 665-672.
76. Canaud BJ: Changing paradigms of renal replacement therapy in chronic kidney disease patients: ultrapure dialysis fluid and highefficiency hemodiafiltration for all? Kidney Int 2009; 76: 591-593.
77. Tetta C, David S, Marcelli D, Cogliati P, Formica M, Inguaggiato P, Panichi V: Clinical effects of online dialysate and infusion fluids. Hemodial Int 2006; 10(suppl 1):S60-S66. (Pubitemid 43272412)
78. Lederer SR, Schiffl H: Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by reducing continuous microinflammation. Nephron 2002; 91: 452-455. (Pubitemid 34765244)
79. Port FK, Pisoni RL, Bragg-Gresham JL, Satayathum SS, Young EW, Wolfe RA, Held PJ: DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif 2004; 22: 175-180.
80. Alquist M, Bosch JP: Treatment mapping: a systematic methodology to assess quality, efficiency and variability in the hemodialysis delivery process. Blood Purif 2008; 26: 417-422.